Stopped early
CorPath GRX STEMI Study
NCT04459299 · Siemens Healthineers Endovascular Robotics, Inc. · Updated 20 Dec 2023
- What is being tested
- Robotic-PCI (CorPath GRX System)
- For
- STEMI - ST Elevation Myocardial Infarction; CAD
- Kind of study
- Watches patients without assigning a treatment. No drug phase (a device or procedure study).
- Who can join
- Ages 18 years to 80 years. About 3 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 28 Sept 2020, ends 29 Nov 2020. Registered 7 July 2020.
- Results
- None posted yet.
In the researchers' words
This study will evaluate the performance of the CorPath GRX System in Robotic Primary PCI (RPPCI) in the treatment of ST-elevated myocardial infarction (STEMI).
Sites
- Wellstar Kennestone HospitalMarietta, Georgia, United States